Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615276 | 1.00 | KMT2A (0.47) | KMT2ASMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL19837332 | 0.82 | MBOAT4 (0.33) | KMT2ASMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL19851266 | 0.77 | KMT2A (0.30) | KMT2A | |
| SCHEMBL10202984 | 0.76 | APP (0.40) | KMT2ASMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL811160 | 0.75 | NPSR1 (0.53) | KMT2ASMN1; SMN2KDM4EL3MBTL1NPSR1 | |
| SCHEMBL29595709 | 0.75 | NPSR1 (0.53) | KMT2ASMN1; SMN2KDM4EL3MBTL1NPSR1 | |
| SCHEMBL29427147 | 0.73 | KMT2A (0.48) | KMT2ASMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL8522 | 0.73 | KMT2A (0.48) | KMT2ASMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL4149032 | 0.73 | TRPV4 (0.60) | KMT2ASMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL26857734 | 0.73 | ESR1 (0.34) | KMT2AALDH1A1TSHRHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109503472-B | Preparation method of heterocyclic sulfone or heterocyclic sulfonamide compound | 嘉兴学院 | 2020-05-22 | — | — | CN | claimed |
| WO-2026101482-A1 | MOLECULAR ORGANIC CRYSTAL-BASED LABELING SYSTEM | T.C. ERCIYES UNIVERSITESI (TR) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| EP-4079724-B1 | 2-(2-CHLOROPHENYL)-N-(5-SULFAMOYLISOQUINOLIN-7-YL)ACETAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS P2X4 ANTAGONISTS FOR THE TREATMENT OF E.G. URINARY TRACT DISEASES | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE | 2025-06-26 | — | — | US | disclosed |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| CN-119638780-A | Nitrogen-containing compound, preparation method and application thereof | 成都地奥制药集团有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-RE50267-E1 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20250009693-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2024120519-A1 | TEAD INHIBITOR, PREPARATION METHOD THEREFOR. AND MEDICAL USE THEREOF | 捷思英达控股有限公司 | 2024-06-13 | — | — | WO | disclosed |
| EP-1805158-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | Kalypsys, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060205736-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060167012-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006055187-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-7041685-B2 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-14 | — | — | US | disclosed |
| CN-1638776-A | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs | CYTOVIA INC (US) | 2005-07-13 | — | — | CN | disclosed |
| EP-1406632-A2 | SUBSTITUTED 3-ARYL-5-ARYL- 1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002100826-A2 | SUBSTITUTED 3-ARYL-5-ARYL-[1,2,4]-OXADIAZOLES AND ANALOGS | CYTOVIA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167012-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | PPARG, PPARA, PPARD | KMT2A 3636/4885SMN1; SMN2 2454/4885MAPT 4471/4885 |
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | YAP1, TEAD1, TEAD2 | KMT2A 1786/4885SMN1; SMN2 2064/4885MAPT 126/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | KMT2A 4396/4885SMN1; SMN2 1064/4885MAPT 3909/4885 |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | ACE2, ACE, TMPRSS2 | KMT2A 3265/4885SMN1; SMN2 3396/4885MAPT 1917/4885 |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, API5 | KMT2A 4129/4885SMN1; SMN2 3205/4885MAPT 4724/4885 |
| US-20250009693-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | KMT2A 4433/4885SMN1; SMN2 1363/4885MAPT 3592/4885 |
| US-20060205736-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | PPARG, PPARA, PPARD | KMT2A 3636/4885SMN1; SMN2 2454/4885MAPT 4471/4885 |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, CASP4 | KMT2A 4312/4885SMN1; SMN2 3329/4885MAPT 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.